Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to know about phase III findings on subcutaneous daratumumab plus pomalidomide and dexamethasone...
Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the challenges for advanced practitioners treating patients with hematologic malignancies who are at high risk for COVID-19 infection...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to know about the findings of the MURANO study, which analyzed patients with relapsed or refractory chronic lymphocytic leukemia who had enduring undetectable minimal residual disease after receiving fixed-duration treatment with venetoclax and rituximab (Abstract 125)...
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses key insights for advanced practitioners from the DREAMM-2 study, which detailed the self-reported experiences of patients with relapsed or refractory multiple myeloma who had treatment-related side effects from belantamab mafodotin (Abstract 3248)...
Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses what advanced practitioners need to know about a novel prognostic index specific to Burkitt lymphoma...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses early insights for advanced practitioners on the safety, efficacy, and toxicities of the drug regimen known as ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) for patients with relapsed or refractory B-cell lymphoma (Abstract 598)...
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to understand about maintenance treatments with carfilzomib and lenalidomide, and conversion from minimal residual disease–positive to –negative in patients with newly diagnosed transplant-eligible multiple myeloma (Abstract 491)...
Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the role advanced practitioners can play in managing the unmet medical needs of patients with primary cold agglutinin disease, many of whom had severe anemia, as well as a high number of hemolysis events, requiring blood transfusions as long as 3 years after diagnosis (Abstract 151)...
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to understand about the findings on safety and efficacy of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes (Abstract 653)...
